The question of the usefulness of Adriamycin has been raised recently. In addition, consider this:
http://www.cancerpage.com/news/article.asp?id=11056
"Exploratory analysis showed significantly better 5-year overall survival rates with leuprorelin (81.0%) compared with CMF (71.9%) and a trend for higher breast cancer-related mortality in the CMF group."